Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure

Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more frequent when associated with concurrent or previous anti-PD(L)...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Guilherme, Santini, Fernando Costa, Canedo, Felipe Sales Nogueira Amorim, de Carvalho Oliveira, Leandro Jonata, Zuppani, Henrique Bortot, De Castro, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834382/
https://www.ncbi.nlm.nih.gov/pubmed/31921341
http://dx.doi.org/10.3332/ecancer.2019.970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834382/
https://www.ncbi.nlm.nih.gov/pubmed/31921341
http://dx.doi.org/10.3332/ecancer.2019.970

Ejemplares similares